IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report)‘s stock had its “overweight” rating restated by Cantor Fitzgerald in a ...

Fintel reports that on January 13, 2025, Cantor Fitzgerald initiated coverage of Camtek (NasdaqGM:CAMT) with a Neutral ...

Eric Johnston, Cantor Fitzgerald chief equity and macro strategist, joins 'Money Movers' to discuss Johnston's thesis for ...

Cantor Fitzgerald raised the firm’s price target on MicroStrategy (MSTR) to $613 from $581 and keeps an Overweight rating on the shares.

Cantor Fitzgerald is charged with violating antifraud and proxy provisions. Former Comtech CEO is charged with insider trading ahead of negative earnings. The Securities and Exchange Commission on ...

Cantor Fitzgerald initiated coverage of Nova (NVMI) with an Overweight rating and $275 price target Stay Ahead of the Market:Discover ...

Analysts at Cantor Fitzgerald initiated coverage on shares of Bright Minds Biosciences (NASDAQ:DRUG – Get Free Report) in a note issued to investors on Friday, MarketBeat.com reports. The brokerage ...

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, commercial-stage biotechnology company with two approved ...

Cantor Fitzgerald Large Cap Focused Fund earns an Above Average Process Pillar rating. The most substantial contributor to the rating is the parent firm's five-year risk-adjusted success ratio of 90%.

As of December 23, 2024, the average one-year price target for SentinelOne is $30.59/share. The forecasts range from a low of $15.15 to a high of $52.50. The average price target represents an ...